Randomized, Double-Blinded, Placebo-Controlled, Open Label Positive- Controlled, Four-Way Crossover Study of the Electrocardiographic Effects of BMS-708163 in Healthy Subjects.

Trial Profile

Randomized, Double-Blinded, Placebo-Controlled, Open Label Positive- Controlled, Four-Way Crossover Study of the Electrocardiographic Effects of BMS-708163 in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2011

At a glance

  • Drugs Avagacestat; Moxifloxacin
  • Indications Alzheimer's disease; Bacterial infections
  • Focus Pharmacodynamics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 20 Jul 2011 Results presented at the 2011 International Conference on Alzheimer's Disease.
    • 15 Apr 2010 Actual end date (February 2010) added as reported by ClinicalTrials.gov.
    • 15 Apr 2010 Actual number of patients added 62 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top